In this regard, a recent study demonstrated that the polyol pathway inhibitor enhances anti-cancer effects of sorafenib by blocking the mTOR pathway, suggesting that the activation of the polyol pathway in HCC may facilitate multityrosine kinase inhibitor escape via alternative pathways [39,40]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.